Of note, FAK has been found activated or up-regulated in several pediatric cancers, such as renal cancer, neuroblastoma, ewing sarcoma, rhabdomyosarcoma and hepatocellular carcinoma, and FAK depletion or pharmacologic inhibition has resulted in tumor growth impairment, both in vitro and in vivo [4,9,22,32,101,102,103,104,105]. The gene discussed is PTK2; the disease is neuroblastoma.